Mind Medicine (MindMed) (DB:MMQ) - Hisse Senedi Fiyatı, Haberler ve Analizler

MMQ Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Mind Medicine (MindMed) Inc. beyin sağlığı bozukluklarını tedavi etmek için yeni ürünler geliştirmektedir. Daha fazla detay

MMQ temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Mind Medicine (MindMed) Inc. Rakipler

PharmaSGP Holding

XTRA:PSG

€287.8m

Dermapharm Holding

XTRA:DMP

€2.0b

MPH Health Care

DB:93M1

€105.3m

Pierrel

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mind Medicine (MindMed)
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.55
52 Haftanın En Yüksek Seviyesi	US$12.03
52 Haftanın En Düşük Seviyesi	US$2.67
Beta	2.33
11 Aylık Değişim	33.75%
3 Aylık Değişim	39.30%
1 Yıllık Değişim	182.98%
33 Yıllık Değişim	-70.91%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	41.39%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MMQ	DE Pharmaceuticals	DE Pazar
7D	3.1%	1.4%	0.8%
1Y	183.0%	-18.4%	9.1%

Getiri vs. Endüstri: MMQ geçen yıl % -18.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: MMQ geçen yıl % 9.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is MMQ's price volatile compared to industry and market?
MMQ volatility
MMQ Average Weekly Movement	12.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: MMQ hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MMQ 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	57	Rob Barrow	www.mindmed.co

Klinik aşamada bir biyofarmasötik şirketi olan Mind Medicine (MindMed) Inc. beyin sağlığı bozukluklarını tedavi etmek için yeni ürünler geliştirmektedir. Şirketin öncü ürün adayları arasında yaygın anksiyete bozukluğu ve dikkat eksikliği hiperaktivite bozukluğunun tedavisi için faz 2'de olan MM-120 ve otizm spektrum bozukluğunun temel semptomlarının tedavisi için faz I klinik çalışmalarında olan 3,4-metilendioksimetamfetaminin bir R-enantiyomeri olan MM-402 yer almaktadır. Mind Medicine (MindMed) Inc. şirketinin merkezi New York, New York'ta bulunmaktadır.

Mind Medicine (MindMed) Inc. Temel Bilgiler Özeti

Mind Medicine (MindMed)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MMQ temel i̇stati̇sti̇kler
Piyasa değeri	€529.16m
Kazançlar(TTM)	-€93.35m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-5.7x

F/K Oranı

MMQ aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MMQ gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$97.80m
Kazançlar	-US$97.80m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.33
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	9.3%

MMQ uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MMQ Stoklara Genel Bakış

Risk Analizi

Mind Medicine (MindMed) Inc. Rakipler

XTRA:PSG

€287.8m

XTRA:DMP

€2.0b

DB:93M1

€105.3m

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

New major risk - Share price stability

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Recent updates

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

New major risk - Share price stability

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold €71k worth of stock

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. Announces Board Appointments

Mind Medicine (MindMed) Receives Non-Compliance Letter from Nasdaq

Mind Medicine (MindMed) Inc. Appoints Schond L. Greenway as Chief Financial Officer

Mind Medicine (MindMed) Inc Reports Topline Data from Phase 1 Trial of MM-110 in Development for Treatment of Opioid Withdrawal

Mind Medicine (MindMed) Inc Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

High number of new and inexperienced directors

Mind Medicine (MindMed) Inc. Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for Lsd in Anxiety Disorders At Psych Symposium

Mind Medicine (MindMed) Inc. Appoints Francois Lilienthal as Chief Commercial Officer

Mindmed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

Mindmed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

U.S. Food and Drug Administration Clears Mind Medicine (MindMed) Inc.'s Investigational New Drug for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. Enrolls the First Subjects into Its Session Monitoring System

Mind Medicine (MindMed) Inc. Successfully Completes Phase 1 Clinical Trial of 18-MC